Sex as a Predictor of Response to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma

Approximately 3–5% of patients with cutaneous squamous cell carcinoma (CSCC) develop advanced disease, accounting for roughly 1% of all cancer deaths in Australia. Immunotherapy has demonstrated significant clinical benefit in advanced CSCC in several key phase II studies; however, there are limited...

Full description

Bibliographic Details
Main Authors: Nicholas Yeo, Benjamin Genenger, Morteza Aghmesheh, Amarinder Thind, Sarbar Napaki, Jay Perry, Bruce Ashford, Marie Ranson, Daniel Brungs
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/15/20/5026